Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: Involvement of peroxisome proliferator-activated receptor-γ and transforming growth factor-β1

Thrombosis and Haemostasis

Volumn 97, Issue 6, 2007, Pages 979-987

  Redondo, Santiago ^a,b   Hristov, Mihail ^b   Gümbel, Denis ^b   Tejerina, Teresa ^a   Weber, Christian ^b  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adhesion; Endothelial; Growth factors; Pharmacology; Pioglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CD31 ANTIGEN; ENDOGLIN; FIBRINOGEN; FIBRONECTIN; LECTIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ANTIGENS, CD; ANTIGENS, CD18; ANTIGENS, CD31; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; RECEPTORS, CELL SURFACE; STEM CELLS; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34250674039     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0593     Document Type: Article

References (45)

1. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
2. Rabelink TJ, de Boer HC, de Koning EJP, et al. Endothelial progenitor cells: more than an inflammatory response? Arterioscler Thromb Vasc Biol 2004; 24: 834-838.
3. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427.
4. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
5. Hristov M, Zernecke A, Bidzhekov K, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597.
6. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
7. Heiss C, Keymel S, Niesler U, et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 2005; 45: 1441-1448.
8. Leor J, Marber M. Endothelial progenitors: a new Tower of Babel? J Am Coll Cardiol 2006; 48: 1588-1590.
9. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-2890.
10. Hristov M, Fach C, Becker C, et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2006; Epub ahead of print.
11. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140: 650-658.
12. Segal MS, Shah R, Afzal A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006; 55: 102-109.
13. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
14. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
15. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
16. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
17. Wang CH, Ciliberti N, Li SH, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004; 109: 1392-1300.
18. Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
19. Redondo S, Ruiz E, Santos-Gallego CG, et al. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-betal, and a Smad2-dependent mechanism. Diabetes 2005; 54: 811-817.
20. Henrich D, Hahn P, Wahl M, et al. Serum derived from multiple trauma patients promotes the differentiation of endothelial progenitor cells in vitro: possible role of transforming growth factor-betal and vascular endothelial growth factor 165. Shock 2004; 21: 13-16.
21. Zernecke A, Weber KS, Erwig LP, et al. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 2001; 166: 5755-5762.
22. Blindt R, Vogt F, Astafieva I, et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol 2006; 47: 1786-1795.
23. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23: 4018-4028.
24. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798.
25. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003; 55: 368-374.
26. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-2067.
27. Pistrosch F, Herbrig K, Oelschlaegel U, et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005; 183: 163-167.
28. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54: 2460-2470.
29. Gensch C, Clever YP, Werner C, et al. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2006; Epub ahead of print.
30. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
31. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002; 51: 58-62.
32. Chavakis E, Aicher A, Heeschen C, et al. Role of ß2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med 2005; 201: 63-72.
33. Duan L, Cheng H, Sun X, et al. LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue. Thromb Haemost 2006; 96: 807-815.
34. Schaefer K, Wada K, Takahashi H, et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65: 2251-2259.
35. Fukunaga Y, Itoh H, Doi K, et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001; 158: 113-119.
36. Sassa Y, Hata Y, Aiello LP, et al. Bifunctional properties of peroxisome proliferator-activated receptor gamma 1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes 2004; 53: 1222-1229.
37. Vogt T, Hafner C, Bross K, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003; 98: 2251-2256.
38. Panigrahy D, Huang S, Kieran MW, et al. PPAR-gamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005; 4: 687-693.
39. Sjolie AK, Moller F. Medical management of diabetic retinopathy. Diabet Med 2004; 21: 666-672.
40. Sales VL, Engelmayr GC, Mettler BA, et al. Transforming growth factor-betal modulates extracellular matrix production, proliferation, and apoptosis of endothelial progenitor cells intissue-engineering scaffolds. Circulation 2006; 114: 1193-1199.
41. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404.
42. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-522.
43. Yamamoto K, Morishita R, Tomita N, et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000; 102: 1308-1314.
44. Lutgens E, Gijbels M, Smock M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982.
45. Watabe T, Nishihara A, Mishima K, et al. TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 2002; 163: 1303-1311.